WuXi Biologics H1 2026 Revenue RMB 11.79B, Net Profit RMB 2.44B
WuXi Biologics released its interim results for the first half of 2026. The company reported revenue of RMB 11.79 billion for the period, an increase of 18.4% year on year. Net profit attributable to owners of the company stood at RMB 2.44 billion, up 4.3% from a year earlier.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceutical R&D Services, with intensity 60/100 and 80% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.